Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial.

Nicolás D, Ambrosioni J, Sued O, Brunet M, López-Diéguez M, Manzardo C, Agüero F, Tuset M, Plana M, Guardo AC, Mosquera MM, Muñoz-Fernández MÁ, Caballero M, Marcos MÁ, Gatell JM, de Lazzari E, Gallart T, Miró JM.

J Antimicrob Chemother. 2017 Mar 1;72(3):829-836. doi: 10.1093/jac/dkw462.

PMID:
27999018
2.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration.

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3. Epub 2015 Jul 7.

3.

Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals.

Hoehn KB, Gall A, Bashford-Rogers R, Fidler SJ, Kaye S, Weber JN, McClure MO; SPARTAC Trial Investigators, Kellam P, Pybus OG.

Philos Trans R Soc Lond B Biol Sci. 2015 Sep 5;370(1676). pii: 20140241. doi: 10.1098/rstb.2014.0241.

4.

Trends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012).

Ambrosioni J, Sued O, Nicolas D, Parera M, López-Diéguez M, Romero A, Agüero F, Marcos MÁ, Manzardo C, Zamora L, Gómez-Carrillo M, Gatell JM, Pumarola T, Miró JM.

PLoS One. 2015 Jun 3;10(6):e0125837. doi: 10.1371/journal.pone.0125837. eCollection 2015.

5.

Structured observations reveal slow HIV-1 CTL escape.

Roberts HE, Hurst J, Robinson N, Brown H, Flanagan P, Vass L, Fidler S, Weber J, Babiker A, Phillips RE, McLean AR, Frater J; SPARTAC trial investigators.

PLoS Genet. 2015 Feb 2;11(2):e1004914. doi: 10.1371/journal.pgen.1004914. eCollection 2015 Feb.

6.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

7.

Incidence of hepatitis C virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: increasing rates of HCV diagnosis but not of HCV seroconversions.

Sobrino-Vegas P, Monge Corella S, Serrano-Villar S, Gutiérrez F, Blanco JR, Santos I, del Romero J, Segura F, Portilla J, Guillén SM, del Amo J; CoRIS.

PLoS One. 2014 Dec 30;9(12):e116226. doi: 10.1371/journal.pone.0116226. eCollection 2014.

8.

Shorter telomere length predicts poorer immunological recovery in virologically suppressed HIV-1-infected patients treated with combined antiretroviral therapy.

Blanco JR, Jarrin I, Martinez A, Siles E, Larrayoz IM, Cañuelo A, Gutierrez F, Gonzalez-Garcia J, Vidal F, Moreno S; CoRIS-Biobanco.

J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):21-9. doi: 10.1097/QAI.0000000000000398.

PMID:
25321176
9.

HIV-1 DNA predicts disease progression and post-treatment virological control.

Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Carrington M, Babiker A, Weber J, Koelsch KK, Kelleher AD, Phillips RE, Frater J; SPARTACTrial Investigators.

Elife. 2014 Sep 12;3:e03821. doi: 10.7554/eLife.03821.

10.

Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes.

Monge S, Diez M, Pulido F, Iribarren JA, Campins AA, Arazo P, Montero M, Miro JM, Moreno S, Del Amo J; Spanish AIDS Research Network Cohort (CoRIS).

Int J Tuberc Lung Dis. 2014 Jun;18(6):700-8. doi: 10.5588/ijtld.13.0778.

PMID:
24903942
11.

HIV-1-specific CD4(+) responses in primary HIV-1 infection predict disease progression.

Frater J, Ewings F, Hurst J, Brown H, Robinson N, Fidler S, Babiker A, Weber J, Porter K, Phillips RE; SPARTAC Trial Investigators.

AIDS. 2014 Mar 13;28(5):699-708. doi: 10.1097/QAD.0000000000000130.

PMID:
24549145
12.

Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study.

Montes Ramírez ML, Miró JM, Quereda C, Jou A, von Wichmann MÁ, Berenguer J, González-García JJ, Hernando A, Ortega E, Sanz J, Arribas JR; GESIDA 3703.FIPSE 36466503-N5 NEAT Study Group.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):82-6. doi: 10.1097/QAI.0b013e3182a685dc.

PMID:
24419065
13.

Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression.

Hamlyn E, Fidler S, Stöhr W, Cooper DA, Tambussi G, Schechter M, Miro JM, Mcclure M, Weber J, Babiker A, Porter K; SPARTAC Trial Investigators.

AIDS. 2014 Mar 27;28(6):869-74. doi: 10.1097/QAD.0000000000000155.

PMID:
24300544
14.

Compliance with national guidelines for HIV treatment and its association with mortality and treatment outcome: a study in a Spanish cohort.

Suárez-García I, Sobrino-Vegas P, Tejada A, Viciana P, Ribas M, Iribarren J, Díaz Menéndez M, Rivero M, Arazo P, Del Amo J, Moreno S; Cohort of the Spanish AIDS Research Network (CoRIS) study group.

HIV Med. 2014 Feb;15(2):86-97. doi: 10.1111/hiv.12078. Epub 2013 Sep 6.

15.

All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997-2010.

Hernando V, Alejos B, Monge S, Berenguer J, Anta L, Vinuesa D, Palacios R, Muga R, Moreno S, Jarrin I; CoRIS cohort.

BMC Infect Dis. 2013 Aug 20;13:382. doi: 10.1186/1471-2334-13-382.

16.

Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters.

Gall A, Kaye S, Hué S, Bonsall D, Rance R, Baillie GJ, Fidler SJ, Weber JN, McClure MO, Kellam P; SPARTAC Trial Investigators.

Retrovirology. 2013 Jan 18;10:8. doi: 10.1186/1742-4690-10-8.

17.

Short-course antiretroviral therapy in primary HIV infection.

SPARTAC Trial Investigators, Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A.

N Engl J Med. 2013 Jan 17;368(3):207-17. doi: 10.1056/NEJMoa1110039.

18.

Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain.

Monge S, Alejos B, Dronda F, Del Romero J, Iribarren JA, Pulido F, Rubio R, Miró JM, Gutierrez F, Del Amo J; CoRIS.

HIV Med. 2013 May;14(5):273-83. doi: 10.1111/hiv.12001. Epub 2012 Nov 21. Erratum in: HIV Med. 2014 Jan;15(1):64.

19.

Longitudinal analysis of an HLA-B*51-restricted epitope in integrase reveals immune escape in early HIV-1 infection.

Yager N, Robinson N, Brown H, Flanagan P, Frater J, Fidler S, Weber J, Phillips R; SPARTAC Trial Investigators.

AIDS. 2013 Jan 28;27(3):313-23. doi: 10.1097/QAD.0b013e32835b8cf5.

PMID:
23095315
20.

Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008-2010.

Jarrin I, Hernández-Novoa B, Alejos B, Riera M, Navarro G, Bernardino JI, Rivero M, del Amo J, Moreno S; CoRIS.

Antivir Ther. 2013;18(2):161-70. doi: 10.3851/IMP2287. Epub 2012 Sep 20.

PMID:
22997147

Supplemental Content

Loading ...
Support Center